×
About 643 results

ALLMedicine™ 5'-nucleotidase Center

Research & Reviews  252 results

Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246388
The Journal of Clinical Investigation; Zhang H, Feng L et. al.

Jul 2nd, 2022 - Immunosuppressive cells accumulating in the tumor microenvironment constitute a formidable barrier that interferes with current immunotherapeutic approaches. A unifying feature of these tumor-associated immune and vascular endothelial cells appear...

Role of the nucleoside-metabolizing enzymes on pain responses in zebrafish larvae.
https://doi.org/10.1016/j.ntt.2022.107109
Neurotoxicology and Teratology; Gusso D, Wiprich MT et. al.

Jul 2nd, 2022 - Purinergic signaling is a pathway related to pain underlying mechanisms. Adenosine is a neuromodulator responsible for the regulation of multiple physiological and pathological conditions. Extensive advances have been made to understand the role o...

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.
https://doi.org/10.1124/pharmrev.121.000528
Pharmacological Reviews; Yegutkin GG, Boison D

Jun 24th, 2022 - Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased rel...

CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357645
Cancer Science; Xue F, Wang T et. al.

Jun 4th, 2022 - Elevated adenosine generated by CD73 (ecto-5'-nucleotidase; NT5E) could boost immunosuppressive responses and promote immune evasion in the tumor microenvironment. However, despite the immune response, CD73 could also promote tumor progression in ...

Screening models combining maternal characteristics and multiple markers for the early ...
https://doi.org/10.1080/01443615.2022.2054675
Journal of Obstetrics and Gynaecology : the Journal of Th... Chen L, Pi Y et. al.

Jun 1st, 2022 - To identify maternal laboratory markers to predict the risk of preeclampsia (PE) in different stages of pregnancy, we analysed 67, 25, and 73, pregnancies developing PE at 11-13, 16-20, and 24-28 wks, respectively. Routine laboratory markers were ...

see more →

Clinicaltrials.gov  5 results

Primary Hyperaldosteronism and Ischemia-reperfusion Injury
https://clinicaltrials.gov/ct2/show/NCT01978132

Oct 12th, 2017 - Patients with PHA have an increased risk of cardiovascular events, independent of blood pressure level. Also in patients suffering a myocardial infarction, circulating aldosterone levels are associated with increased mortality. In animal models of...

ACCEL-LOADING-ACS Study
https://clinicaltrials.gov/ct2/show/NCT01354808

Sep 24th, 2013 - In ACS patients, platelet activation, inflammation, and ischemia-reperfusion injury can be closely associated with the risk of post-PCI myonecrosis and ischemic events occurrence. In the ACCEL-AMI (Adjunctive Cilostazol versus high maintenance-dos...

Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?
https://clinicaltrials.gov/ct2/show/NCT00851175

Oct 1st, 2009 - Rationale: Statins form a class of drugs that is widely prescribed for hypercholesterolaemia, specifically to reduce the risk on atherosclerosis by lowering LDL-cholesterol. Next to the effect for which the drug was originally developed, it became...

Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?
https://clinicaltrials.gov/ct2/show/NCT00457652

Apr 15th, 2008 - Rosuvastatin is a proven cholesterol lowering medicine, which hereby is assumed to achieve a reduction in cardiovascular events. Apart from it's cholesterol lowering action, rosuvastatin may also increase tolerance against ischemia-reperfusion inj...

Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
https://clinicaltrials.gov/ct2/show/NCT00004658

Jun 24th, 2005 - PROTOCOL OUTLINE: Newly identified patients receive ribose daily for 8 weeks. Patients who improve continue therapy. If improvement then reaches a plateau, uridine (UR) and thymidine (TDR) are added to the regimen. Patients who receive no benefit ...

see more →